SAN

77.23

+0.93%↑

ARGX

698.2

+0.11%↑

SHL.DE

34.84

+0.11%↑

FRE

38.2

-0.24%↓

PHIA

23.59

+0.47%↑

SAN

77.23

+0.93%↑

ARGX

698.2

+0.11%↑

SHL.DE

34.84

+0.11%↑

FRE

38.2

-0.24%↓

PHIA

23.59

+0.47%↑

SAN

77.23

+0.93%↑

ARGX

698.2

+0.11%↑

SHL.DE

34.84

+0.11%↑

FRE

38.2

-0.24%↓

PHIA

23.59

+0.47%↑

SAN

77.23

+0.93%↑

ARGX

698.2

+0.11%↑

SHL.DE

34.84

+0.11%↑

FRE

38.2

-0.24%↓

PHIA

23.59

+0.47%↑

SAN

77.23

+0.93%↑

ARGX

698.2

+0.11%↑

SHL.DE

34.84

+0.11%↑

FRE

38.2

-0.24%↓

PHIA

23.59

+0.47%↑

Home・Aandelen Lijst・Fagron

Fagron

Open

SectorGezondheidszorg

25.1 0.2

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

25.2

Belangrijke statistieken
By Trading Economics
Inkomsten	-99K 45M
Verkoop	-98K 476M
K/W Sectorgemiddelde	19.597 49.701
Dividendrendement	1.66
Winstmarge	9.55
Werknemers	4,193
EBITDA	11M 98M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+20.59% upside

Dividenden
By Dow Jones
Dividendrendement Sectorgemiddelde	1.66% 2.39%
Volgende Winsten	30 jul 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	153M 1.8B
Vorige openingsprijs	24.9
Vorige sluitingsprijs	25.1

Nieuwssentiment

By Acuity

50%

159 / 345 Rangschikking in Healthcare

Fagron Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

25 mei 2026, 08:24 UTC

Belangrijke Marktbewegers

Acquisities, Fusies, Overnames

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 mei 2026, 21:22 UTC

Winsten

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 mei 2026, 20:50 UTC

Marktinformatie

Winsten

Basic Materials Roundup: Market Talk

25 mei 2026, 16:20 UTC

Marktinformatie

Winsten

Basic Materials Roundup: Market Talk

25 mei 2026, 16:01 UTC

Marktinformatie

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 mei 2026, 14:43 UTC

Marktinformatie

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 mei 2026, 14:15 UTC

Marktinformatie

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 mei 2026, 13:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

25 mei 2026, 12:58 UTC

Marktinformatie

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 mei 2026, 12:56 UTC

Marktinformatie

Winsten

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 mei 2026, 12:48 UTC

Marktinformatie

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 mei 2026, 12:48 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

25 mei 2026, 12:34 UTC

Marktinformatie

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 mei 2026, 12:10 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Delivery Hero's Assets Look Strategic -- Market Talk

25 mei 2026, 11:00 UTC

Marktinformatie

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 mei 2026, 10:19 UTC

Marktinformatie

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 mei 2026, 10:05 UTC

Winsten

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 mei 2026, 10:04 UTC

Winsten

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 mei 2026, 10:03 UTC

Winsten

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 mei 2026, 10:02 UTC

Winsten

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 mei 2026, 10:01 UTC

Winsten

Tenaga Nasional 1Q Net Up 3.7% on Year

25 mei 2026, 10:00 UTC

Winsten

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 mei 2026, 09:56 UTC

Winsten

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 mei 2026, 09:56 UTC

Winsten

Tenaga Nasional 1Q EPS MYR0.1883

25 mei 2026, 09:56 UTC

Winsten

Tenaga Nasional 1Q Rev MYR17.1B

25 mei 2026, 09:56 UTC

Winsten

Tenaga Nasional 1Q Net MYR1.1B

25 mei 2026, 09:38 UTC

Marktinformatie

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 mei 2026, 09:33 UTC

Marktinformatie

Global Equities Roundup: Market Talk

25 mei 2026, 09:33 UTC

Marktinformatie

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 mei 2026, 08:55 UTC

Marktinformatie

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Peer Vergelijking

Prijswijziging

Fagron Prognose

Koersdoel

By TipRanks

20.59% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 19.5 EUR 20.59%

Hoogste 19.5 EUR

Laagste 19.5 EUR

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Fagron - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan Fagron - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

159 / 345 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Fagron

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.